The drug is intended for intravascular (intra-arterial, intravenous), intrathecal, intracavitary, oral and rectal administration. Like all drugs for parenteral administration, Yogeksol must be visually inspected before use for insoluble particles, discoloration and damage to the integrity of the package.
Yogeksol should be drawn into a syringe just before use. Unused residues of the drug are not allowed for further use.
Yogeksol should not be mixed with other medicines (you must use a separate syringe and needle).
When injecting the drug, the patient should be in a horizontal position. Within 30 minutes after the end of the procedure, medical supervision of the patient is carried out, since most of the adverse reactions occur during this period.
After performing myelography, the patient should be at rest for at least 1 hour, lying with the head of the bed raised by 20 °. If you suspect a low threshold for the development of seizures, it is necessary to observe the subject for 6 hours. Patients on an outpatient basis should avoid bending over. Outpatients should not be left unattended for the first 24 hours after administration of a radiopaque contrast agent.
The dosage of the drug depends on the type of study, the age and body weight of the patient, as well as the state of hemodynamics, general health, as well as the methodology and technique used for performing the study. Usually, the same iodine concentrations and volumes of drug administration are used as with other modern iodine-containing X-ray contrast media.
Intravenous (IV) administration:
300 mg iodine/ml or 350 mg iodine/ml (40-80 ml). In some cases, it is possible to administer more than 80 ml